Apollon Wealth Management LLC Has $28.18 Million Position in Eli Lilly and Company (NYSE:LLY)

Apollon Wealth Management LLC boosted its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 73.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 34,117 shares of the company's stock after buying an additional 14,466 shares during the period. Apollon Wealth Management LLC's holdings in Eli Lilly and Company were worth $28,177,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Hohimer Wealth Management LLC grew its holdings in shares of Eli Lilly and Company by 99.3% during the first quarter. Hohimer Wealth Management LLC now owns 1,443 shares of the company's stock worth $1,192,000 after purchasing an additional 719 shares during the last quarter. Bogart Wealth LLC lifted its stake in Eli Lilly and Company by 12.5% in the first quarter. Bogart Wealth LLC now owns 486 shares of the company's stock valued at $402,000 after buying an additional 54 shares during the period. Catalyst Financial Partners LLC lifted its stake in Eli Lilly and Company by 2.0% in the first quarter. Catalyst Financial Partners LLC now owns 5,029 shares of the company's stock valued at $4,154,000 after buying an additional 98 shares during the period. Cohen Capital Management Inc. lifted its stake in Eli Lilly and Company by 37.9% in the first quarter. Cohen Capital Management Inc. now owns 466 shares of the company's stock valued at $385,000 after buying an additional 128 shares during the period. Finally, Signaturefd LLC increased its holdings in shares of Eli Lilly and Company by 1.4% in the first quarter. Signaturefd LLC now owns 25,687 shares of the company's stock worth $21,215,000 after acquiring an additional 367 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Up 0.3%

Shares of NYSE:LLY opened at $793.34 on Monday. The company has a market capitalization of $751.88 billion, a price-to-earnings ratio of 64.55, a P/E/G ratio of 1.16 and a beta of 0.40. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.37 and a quick ratio of 1.06. The business's 50-day moving average is $766.39 and its 200-day moving average is $800.06. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The firm had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. During the same period last year, the company posted $2.58 earnings per share. The firm's quarterly revenue was up 45.2% compared to the same quarter last year. Equities research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be paid a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.76%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company's dividend payout ratio (DPR) is currently 48.82%.

Analysts Set New Price Targets

LLY has been the subject of several recent analyst reports. Wells Fargo & Company restated an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Hsbc Global Res downgraded Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research note on Monday, April 28th. Guggenheim raised their price objective on Eli Lilly and Company from $936.00 to $942.00 and gave the company a "buy" rating in a research report on Friday. Morgan Stanley reaffirmed an "overweight" rating and issued a $1,135.00 price objective (up from $1,133.00) on shares of Eli Lilly and Company in a research report on Thursday. Finally, UBS Group dropped their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a report on Friday, May 2nd. One research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $1,012.56.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.